Can Dash Bio’s $30m automation bet break one of drug development’s slowest bottlenecks?
Dash Bio’s $30 million Series A backs automated bioanalysis expansion, but validation, scale and sponsor adoption will determine its impact.
Medical Devices & Diagnostics
Pharma & Biotech
What the Obsidian Therapeutics and Galera Therapeutics merger means for OBX-115
Obsidian Therapeutics closes its Galera merger and $350 million financing, putting OBX-115 melanoma data and execution under investor scrutiny.
Medical Devices & Diagnostics
GE HealthCare expands dense breast screening portfolio with Invenia ABUS Prime and ABUS StreamVue
GE HealthCare launches Invenia ABUS Prime and ABUS StreamVue, targeting scalable dense breast screening and enterprise-wide review.
Medical Devices & Diagnostics
Cizzle Bio’s South Texas laboratory deal widens CIZ1B reach, but the real test starts now
Cizzle Bio’s BioBridge Global collaboration widens CIZ1B access in South Texas, but validation, reimbursement and evidence remain decisive.
Pharma & Biotech
What FDA’s latest ibezapolstat guidance means for Acurx and the IBZ-ASPIRE trial
FDA feedback may let Acurx use one Phase 3 ibezapolstat trial for C. difficile treatment and recurrence, but evidence and funding remain decisive.
Pharma & Biotech
Lilly’s rare pancreatic cancer target just gained FDA momentum, but olomorasib still faces its hardest test
Eli Lilly and Company has secured an expedited United States regulatory pathway for olomorasib in a rare, previously treated pancreatic cancer population. The designation increases FDA engagement around the programme, but the investigational therapy still needs a pancreatic cancer-specific evidence package capable of supporting approval.
Medical Devices & Diagnostics
Can Invenio Imaging’s AI deliver reliable lung biopsy feedback inside the bronchoscopy room?
Invenio Imaging completes ON-SITE enrolment as NIO Lung Cancer Reveal moves toward pivotal analysis and a potential FDA submission.
Pharma & Biotech
AusperBio has entered the HBV siRNA race, but can AHB-171 move beyond antigen suppression?
AusperBio has dosed the first patient with AHB-171, testing a liver-targeted siRNA candidate and a broader combination strategy for hepatitis B.
Pharma & Biotech
Incyte’s Minjuvi gains Australian reimbursement after TGA follicular lymphoma registration
Australia has listed Minjuvi on the PBS for relapsed follicular lymphoma. See what the inMIND data and access terms mean.
Pharma & Biotech
Mezzion’s new kidney disease data sent shares higher, but the decisive test is still ahead
Mezzion reports animal-model ADPKD data for udenafil as it prepares Phase 2b testing. The findings support development, but human efficacy is unproven.